RedChip.com - Small-Cap Stock Portfolio <span style=' color: rgb(255, 255, 255); text-shadow: 2px 2px 1px #1b1b1b; font-size: 40px;'>Sorrento Therapeutics<br /><em style='font-weight:400; font-size:34rem;'>(NASDAQ: SRNE)</em></span><br /> - RedChip.com

Sorrento Therapeutics
(NASDAQ: SRNE)

 Fact Sheet

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T"), intracellular targeting antibodies ("iTAbs"), antibody-drug conjugates ("ADC"), and clinical stage oncolytic virus ("Sephrevir®").

Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin ("RTX") and ZTlido. Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido is in regulatory review following NDA re-submission.



Company Name Sorrento Therapeutics
Market/Symbol NASDAQ: SRNE
Industry Biopharma
Recent Price
Market Cap$284.90M
Shares Outstanding$122.28M
Avg. Daily Vol. (3m)1,611,582
Price/Cash Flow N/A
As of Mar. 18, 2019
*Source: QuoteMedia

SIGN UP FOR EMAIL ALERTS

BE THE FIRST TO RECEIVE BREAKING NEWS

Recent Company Videos


Sorrento Therapeutics: Exclusive Investor Presentation

Feb. 2, 2018

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets…


Sorrento Therapeutics Latest News


Latest Investor Presentation

Latest Investor Presentation

 Download

SRNE Research

Sorrento is a revenue generating biopharmaceutical company with a robust development pipeline of clinical trials. The Company is in IND filing for its potential-blockbuster immuno-oncology… Read More

Jan. 12, 2018

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Receive SRNE Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market